Velpatasvir

Category: pharmacological

Aliases: Component of Epclusa

Pharmacological Mechanism

Pan-genotypic HCV NS5A inhibitor — combined with sofosbuvir as Epclusa for 12-week pan-genotypic regimen including decompensated cirrhosis. CYP2C8 + CYP2B6 + CYP3A4 substrate; gastric acid required for absorption (PPI co-administration lowers F).

Half-Life (t½)

PO: 15h

Dosing Guidelines

• PO: Typical 100 mg (Range: 100–100 mg)

Target Organ Systems

• digestive
• immune-hematologic

Pathways It Modulates

• HCV NS3/4A / NS5A / NS5B replication targets (inhibitor) — NS5A

Chemical Identifiers

• PubChem CID: 67683363
• Formula: C49H54N8O8
• Molecular weight: 883.02 g/mol
• InChIKey: FHCUMDQMBHQXKK-CDIODLITSA-N
• SMILES: C[C@H]1CC[C@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C2=NC3=C(N2)C=CC4=CC5=C(C=C43)OCC6=C5C=CC(=C6)C7=CN=C(N7)[C@@H]8C[C@@H](CN8C(=O)[C@@H](C9=CC=CC=C9)NC(=O)OC)COC

References

• PMID 28193657